NCT06908382招募中2 期
A Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Chemotherapy as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- pCR Rate
研究概览
简要总结
This study plans to enroll 32 patients with resectable esophageal squamous cell carcinoma. The treatment regimen consists of Iparomlimab and Tuvonralimab(QL1706) combined with chemotherapy: intravenous infusion of QL1706 (5 mg/kg, q3w) in combination with albumin-bound paclitaxel (260 mg/m² on day 1, q3w) plus cisplatin (75 mg/m² on day 1, q3w) or carboplatin (AUC 5 on day 1, q3w) for 3 cycles. Surgical resection will be performed 3-6 weeks after treatment completion. Pre-treatment and surgical tissue specimens will be collected for analysis of tumor immune microenvironment changes using digital gene quantification technology. Peripheral blood samples will be obtained for dynamic ctDNA monitoring at four time points: within 7 days pre-treatment, 7 days pre-surgery, 7-30 days post-surgery, and 6 months post-surgery. The primary endpoint is the pathological complete response (pCR) rate, and secondary endpoints include major pathological response (MPR) and adverse reactions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent form to voluntarily join this study;
- •Age 18-75 years old, male or female;
- •ECOG PS 0-1;
- •Planned surgical treatment after completion of neoadjuvant therapy;
- •Patients with esophageal squamous cell carcinoma diagnosed pathologically as ct1b-ct2n+or ct3-ct4a any nm0
排除标准
- •The subject has any active autoimmune disease or history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; the subject suffers from vitiligo; asthma has been completely relieved in childhood and does not need any intervention after adulthood can be included, but asthma that needs bronchodilators for medical intervention cannot be included);
- •The subjects are using immunosuppressive agents or systemic or absorbable local hormones to achieve the purpose of immunosuppression (dose>10mg/day prednisone or other effective hormones), and continue to use them within 2 weeks before enrollment;
- •Severe allergic reaction to other monoclonal antibodies;
- •There are cardiac clinical symptoms or diseases that are not well controlled, such as: (1) heart failure above NYHA grade 2 (2) unstable angina pectoris (3) myocardial infarction within one year (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention (5) qtc>450ms (male); Qtc>470ms (female);
- •Patients at risk of massive bleeding
- •Abnormal coagulation function (inr>1.5 or pt>16s), bleeding tendency or undergoing thrombolytic or anticoagulant therapy;
- •Genetic or known to exist Acquired hemorrhage and thrombotic tendency (such as hemophilia, coagulation dysfunction, thrombocytopenia, hypersplenism, etc.) or arteriovenous thrombosis events in recent 6 months (until the first use of shr-1210);
- •Subjects with active infection or fever of unknown origin>38.5 degrees during screening and before the first administration;
- •Patients with previous and current objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, and severe impairment of lung function;
- •Subjects with congenital or acquired immune deficiency (such as HIV infected), or active hepatitis (hepatitis B reference: HBV DNA detection value exceeds the upper limit of normal value; Hepatitis C reference: HCV virus titer or RNA detection value exceeds the upper limit of normal value);
- •Those who have used other drugs in clinical trials within 4 weeks before the first medication;
- •The subjects had previously or simultaneously suffered from other malignant tumors;
- •Subjects may receive other systemic anti-tumor treatment during the study period;
- •The subjects had previously received other PD-1 antibody therapy or other immunotherapy for PD-1/PD-L1;
- •Live vaccines were administered less than 4 weeks before the study or during the study period;
- •According to the judgment of the investigator, the subject has other factors that may lead to the forced termination of this study, such as other serious diseases (including mental diseases) requiring combined treatment, serious laboratory abnormalities, accompanied by family or social factors, which will affect the safety of the subject, or the collection of data and samples.
研究组 & 干预措施
experimental group
Experimental
干预措施: Iparomlimab and Tuvonralimab Injection (Drug)
结局指标
主要结局
pCR Rate
时间窗: one month after esophageal cancer surgery
The rate of patients with primary tumor and lymph nodes both achieved pathological complete response
次要结局
- MPR Rate(one month after esophageal cancer surgery)
- EFS(approximately 5 years)
- OS(approximately 6 years)
- Safety (adverse event)(From initial drug use to one month after surgery)
研究者
Yang Zhe
Tumor Research and Therapy Center
Shandong Provincial Hospital
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCCSquamous Cell Carcinoma of Head and NeckNCT06081582First Affiliated Hospital of Zhejiang University33
进行中（未招募）
2 期
Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic CancerPancreatic CancerNCT06766019The First Affiliated Hospital with Nanjing Medical University47
招募中
2 期
Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell CarcinomaToripalimabFirst-line TreatmentNCT05760053Sun Yat-sen University33
招募中
2 期
A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell CarcinomaNCT06843889Nanfang Hospital, Southern Medical University34
尚未招募
2 期
Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)Non Small Cell Lung Cancer RecurrentNCT05842018Tianjin Medical University Cancer Institute and Hospital30